VIDAC PHARMA HOLDING PLC
Commented by Juliane Zielonka on December 23rd, 2024 | 11:55 CET
Pharma stocks in focus: Setback for Novo Nordisk, spot-on performance for Vidac Pharma and Bayer
Updates from the pharmaceutical and biotech sector for investors: The Danish company Novo Nordisk is experiencing a setback in the development of its new weight loss drug, CagriSema. Vidac Pharma and Bayer, on the other hand, have positive news to report. The biotech company has received an extension of patent protection for its innovative cancer drugs from the US Patent Office, presenting a unique opportunity for investors. Bayer is also celebrating a success: the higher-dose version of the eye drug Eylea has delivered convincing results in the latest study. This means that in the future, patients will require less frequent injections into the eye. We take a closer look at the developments.
Read
Commented by Fabian Lorenz on December 19th, 2024 | 07:00 CET
Evotec, Rheinmetall, Vidac Pharma: Buy recommendation, cancer revolution, or price collapse?
Analysts see significant potential for multiplication with Vidac Pharma's stock. It has already been one of the standout performers in the biotech sector in the second half of the year. The Company aims to revolutionize cancer treatment and has published the next top news. Analysts also see further price potential for Rheinmetall. However, shareholders should brace themselves for a possible significant correction in the share price of Germany's largest defense contractor. By contrast, opinions on Evotec remain divided. Is the share price at risk of halving again after a year to forget? Or is now the time to buy in?
Read
Commented by André Will-Laudien on December 10th, 2024 | 07:00 CET
Biotech Acquisitions in 2025: Several 100% Gains Expected – Evotec, Vidac Pharma, BioNTech, and Pfizer
There have already been two attempts, but the story continues! Evotec speculators were confronted with a rumor mill and a takeover bid in November. This is what happens when a stock plummets and languishes for a long time. The management wisely rejected Halozyme's undervalued offer, and thus, the bidding war for the Hamburg-based company began anew. In the biotech sector, eyes should now be on the future, as the first movements have already taken place. In our stock selection, there are three outliers with price increases of more than 30% in the last 3 months. However, the big moves will only take place in 2025. Here is an analytical look at a long-neglected sector.
Read
Commented by Armin Schulz on December 2nd, 2024 | 07:20 CET
Evotec, Vidac Pharma, BioNTech – Cancer research: The gold mine in the portfolio
Investing in publicly traded companies active in oncology research offers promising returns and long-term stability. The oncology market is one of the fastest-growing sectors in healthcare and benefits from an ever-increasing demand for innovative and personalized cancer therapies. Advances such as CAR-T cell therapies and antibody-drug conjugates are revolutionizing treatment options and creating new opportunities for companies and investors. At the same time, the sector is characterized by a low dependence on economic fluctuations and a high level of dynamism in mergers and acquisitions. With long-term trends such as an aging population, this market offers solid prospects for investors. We take a look at three promising companies.
Read
Commented by Fabian Lorenz on November 18th, 2024 | 07:00 CET
Takeover speculation and momentum: BioNTech, Rheinmetall, Vidac Pharma
BioNTech aims to strengthen its cancer-fighting pipeline by acquiring the Chinese biotech firm Biotheus. The Mainz-based company is laying out up to USD 950 million for the company, which specializes in the development of therapies for cancer and autoimmune diseases. This is the latest example of takeovers in the cancer sector. Vidac Pharma, with a market capitalization of just over EUR 30 million, appears to be favorably valued. Analysts share this view, as Vidac is working on a revolutionary cancer therapy. While Vidac's share price jumped in the second half of the year, Rheinmetall consolidated. Will the defense stock be able to break out with the tailwind from Trump?
Read
Commented by André Will-Laudien on November 14th, 2024 | 07:15 CET
The acquisition carousel is gaining momentum! Evotec, Vidac Pharma, BioNTech, and Formycon in focus
The biotech sector is in the spotlight again today. Triton's entry into Evotec means that another deal is in the works, and investors should now take notice. Many still remember MorphoSys, where there were short-term gains of up to 400% at the beginning of the year. Before that, the stock had been trading with high volumes. Will Formycon or Vidac Pharma be next on the list? Formycon is now getting significantly more attention because the stock switched to the Prime Standard. Evotec has once again disappointed operationally, yet the value has increased by a good 50% in just two months. Those who analyze carefully can profit again. A sharp analytical eye is worthwhile.
Read
Commented by Juliane Zielonka on November 7th, 2024 | 07:00 CET
Vidac Pharma, BioNTech, Bayer - Billion-Dollar Gene Therapy Market Attracts Investors
Two trends are emerging in the pharmaceutical industry: personalized medicine, which tailors therapies to the genetic profile of individual patients, and the development of highly specific active ingredients that target biological mechanisms. Vidac Pharma is one of the companies focusing on these targeted therapies and recently received a groundbreaking US patent for its innovative approach to normalizing cancer cell metabolism - a concept known as the "Warburg effect reversal." BioNTech is driving its transformation from COVID-19 vaccine producer to cancer specialist, with promising Phase II trials underway for treatments targeting lung and breast cancers. Bayer, meanwhile, is under pressure due to disappointing sales of its partner Regeneron's eye drug Eylea® – the second most important product in the portfolio, which has to hold its own against growing competition. Where is an investment worthwhile?
Read
Commented by André Will-Laudien on October 24th, 2024 | 07:30 CEST
Biotech – Are takeovers looming amidst curious prices? Evotec, Bayer, Vidac Pharma and BioNTech in the spotlight
The biotech sector is once again in the spotlight. Since the acquisition of MorphoSys at the beginning of the year, the speculation carousel is turning again. Is Evotec next, or maybe Vidac Pharma? The Hamburg-based drug specialist came under fire from short-sellers after the resignation of long-standing CEO Lanthaler, who had shorted over 4% of the capital by mid-September. However, the price stubbornly held above the EUR 5 mark, and yesterday saw a 10% rise to EUR 6.60. What is behind this? Last week, it was Vidac Pharma that surged 300% from a standing start with enormous trading volumes. The thought processes of market participants are evident: interest rates are falling, making refinancing attractive again for upcoming financial investors. We shed light on the key players.
Read
Commented by Stefan Feulner on October 14th, 2024 | 07:00 CEST
Bayer, Vidac Pharma, Evotec – Enormous potential
Since the US Federal Reserve cut key interest rates and signaled a continuation of its loose monetary policy, the Nasdaq Biotech Index has been on an upward trajectory and has significantly outperformed the broader market in recent days. The correction of the past few months seems to be over in this sector, and the all-time high from August 2021 is within reach. In addition to rising share prices, the number of acquisitions is also increasing significantly, a sign of the undervaluation of many listed companies.
Read
Commented by Fabian Lorenz on October 9th, 2024 | 07:15 CEST
Biotech comeback and takeover fantasy! BioNTech, Bayer, and Vidac Pharma
Money can be made in biotech shares again! However, investors need to look carefully. While Moderna is at a multi-year low, BioNTech and Vidac Pharma have gained over 50% in just a few months. Is there more to come? The chances are good, as both biotech companies have released promising news. Analysts see a tenfold increase in the case of Vidac Pharma, and the focus on the fight against cancer makes the Company a takeover candidate. The cancer specialist would also be a good fit for Bayer and BioNTech, and the share is still cheap. BioNTech is becoming an investment darling again and is focusing on AI. Bayer has yet to make the leap above EUR 30, and analysts are warning about the upcoming quarterly figures.
Read